CHAMPION PHOENIX Phase III trial of cangrelor (Medicines Company) success in PCI
The Medicines Company has reported results of CHAMPION PHOENIX, a 11,145 patient Phase III randomized, double-blind clinical trial comparing the Company's intravenous antiplatelet cangrelor to oral clopidogrel in patients undergoing Percutaneous Coronary Intervention (PCI).
Patients treated with cangrelor had a 22% (p=0.005) reduced odds of experiencing the primary endpoint, which was a composite incidence of death, myocardial infarction (MI), ischemia-driven revascularization (IDR) or stent thrombosis (ST) at 48 hours after randomization. Cangrelor also showed a 38% reduction in the odds of the key secondary endpoint, incidence of stent thrombosis at 48 hours.
The Medicines Company will file for regulatory approval in the U.S. and Europe in the next quarter 2013.
see -"Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events"- Deepak L. Bhatt, M.D., M.P.H., Gregg W. Stone, M.D., Kenneth W. Mahaffey, M.D., C. Michael Gibson, M.D., Prats, Ph.D., Meredith Todd, B.Sc., Simona Skerjanec, Pharm.D., Harvey D. White, D.Sc., Robert A. Harrington, M.D. et al., for the CHAMPION PHOENIX Investigators -March 10, 2013DOI: 10.1056/NEJMoa1300815 .
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins